-
Signature
-
/s/ Vijay Iyer, Attorney-in-Fact
-
Stock symbol
-
BKNG
-
Transactions as of
-
Nov 17, 2025
-
Transactions value $
-
-$2,003,074
-
Form type
-
4
-
Date filed
-
11/19/2025, 07:35 AM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Fogel Glenn D |
CEO AND PRESIDENT, Director |
BOOKING HOLDINGS INC., 800 CONNECTICUT AVENUE, NORWALK |
/s/ Vijay Iyer, Attorney-in-Fact |
2025-11-19 |
0001516908 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.7K |
-10 |
-0.05% |
$4,873.79 |
22.1K |
Nov 17, 2025 |
Direct |
F1, F2 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.8K |
-10 |
-0.05% |
$4,884.87 |
22.1K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.9K |
-10 |
-0.05% |
$4,892.40 |
22.1K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$49.1K |
-10 |
-0.05% |
$4,908.60 |
22.1K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$49.8K |
-10 |
-0.05% |
$4,975.74 |
22.1K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50K |
-10 |
-0.05% |
$4,996.76 |
22.1K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$150K |
-30 |
-0.14% |
$4,999.23 |
22.1K |
Nov 17, 2025 |
Direct |
F1, F3 |
| transaction |
BKNG |
Common Stock |
Sale |
-$100K |
-20 |
-0.09% |
$5,003.05 |
22K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50K |
-10 |
-0.05% |
$5,004.23 |
22K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$100K |
-20 |
-0.09% |
$5,009.47 |
22K |
Nov 17, 2025 |
Direct |
F1, F4 |
| transaction |
BKNG |
Common Stock |
Sale |
-$100K |
-20 |
-0.09% |
$5,012.58 |
22K |
Nov 17, 2025 |
Direct |
F1, F5 |
| transaction |
BKNG |
Common Stock |
Sale |
-$150K |
-30 |
-0.14% |
$5,015.75 |
22K |
Nov 17, 2025 |
Direct |
F1, F6 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.2K |
-10 |
-0.05% |
$5,017.24 |
22K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.2K |
-10 |
-0.05% |
$5,020.80 |
21.9K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.2K |
-10 |
-0.05% |
$5,024.25 |
21.9K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$101K |
-20 |
-0.09% |
$5,025.98 |
21.9K |
Nov 17, 2025 |
Direct |
F1, F7 |
| transaction |
BKNG |
Common Stock |
Sale |
-$101K |
-20 |
-0.09% |
$5,027.28 |
21.9K |
Nov 17, 2025 |
Direct |
F1, F8 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.3K |
-10 |
-0.05% |
$5,028.11 |
21.9K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.3K |
-10 |
-0.05% |
$5,030.11 |
21.9K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$151K |
-30 |
-0.14% |
$5,033.31 |
21.8K |
Nov 17, 2025 |
Direct |
F1, F9 |
| transaction |
BKNG |
Common Stock |
Sale |
-$151K |
-30 |
-0.14% |
$5,035.30 |
21.8K |
Nov 17, 2025 |
Direct |
F1, F10 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.4K |
-10 |
-0.05% |
$5,036.25 |
21.8K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$50.4K |
-10 |
-0.05% |
$5,037.77 |
21.8K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$101K |
-20 |
-0.09% |
$5,039.89 |
21.8K |
Nov 17, 2025 |
Direct |
F1, F11 |
| transaction |
BKNG |
Common Stock |
Sale |
-$101K |
-20 |
-0.09% |
$5,044.64 |
21.8K |
Nov 17, 2025 |
Direct |
F1, F12 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: